Genprex (Nasdaq:GNPX) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

GNPX Overzicht aandelen

Genprex, Inc., een gentherapiebedrijf in een klinische fase, richt zich op de ontwikkeling van therapieën voor patiënten met kanker en diabetes.

Over het bedrijf

GNPX fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft minder dan 1 jaar cash runway

De winst zal naar verwachting de komende drie jaar met gemiddeld 12.2% per jaar dalen.

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

+ 3 meer risico's

Genprex, Inc. Concurrenten

Windtree Therapeutics

NasdaqCM:WINT

US$1.2m

NeuBase Therapeutics

NasdaqCM:NBSE

US$1.4m

CohBar

OTCPK:CWBR

US$1.5m

Revelation Biosciences

NasdaqCM:REVB

US$1.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Genprex
Historische aandelenkoersen
Huidige aandelenkoers	US$0.33
52 Week Hoogtepunt	US$15.60
52 Week Laag	US$0.28
Bèta	-0.57
11 maand verandering	-51.81%
3 maanden verandering	-82.72%
1 Jaar Verandering	-97.77%
33 jaar verandering	-99.68%
5 jaar verandering	-98.68%
Verandering sinds IPO	-99.82%

Recent nieuws en updates

Recent updates

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Aug 15

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Jun 14

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Feb 09

Genprex: Limited Clinical Data To Justify Risk

Nov 19

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Oct 27

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Jun 11

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

May 05

Genprex' stock jumps after corporate update

Feb 01

Genprex achieves manufacturing milestone for immunogene therapy for upcoming lung cancer trials

Jan 13

Genprex completes manufacturing scale-up of lung cancer therapy

Dec 22

Rendement voor aandeelhouders

	GNPX	US Biotechs	US Markt
7D	-5.8%	-0.2%	-0.4%
1Y	-97.8%	22.1%	34.1%

Rendement versus industrie: GNPX presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 22.1 % opleverde.

Rendement versus markt: GNPX presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 34.1 % opleverde.

Prijsvolatiliteit

Is GNPX's price volatile compared to industry and market?
GNPX volatility
GNPX Average Weekly Movement	14.7%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van GNPX is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 15% ) van GNPX is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	21	Ryan Confer	www.genprex.com

Genprex, Inc., een gentherapiebedrijf in een klinische fase, richt zich op de ontwikkeling van therapieën voor patiënten met kanker en diabetes. De technologieën van het bedrijf zijn ontworpen om ziektebestrijdende genen toe te dienen voor nieuwe therapieën voor patiëntenpopulaties met kanker en diabetes. Het oncologieprogramma maakt gebruik van het systemische, niet-virale Oncoprex Delivery System, dat genexpressieplasmiden inkapselt door middel van lipidegebaseerde nanodeeltjes in lipoplexvorm.

Genprex, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Genprex zich tot de beurswaarde?
GNPX fundamentele statistieken
Marktkapitalisatie	US$1.27m
Inkomsten(TTM)	-US$26.14m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is GNPX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GNPX resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$26.14m
Inkomsten	-US$26.14m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-7.26
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde GNPX op de lange termijn?

Bekijk historische prestaties en vergelijking

GNPX Overzicht aandelen

Beloningen

Risicoanalyse

Genprex, Inc. Concurrenten

NasdaqCM:WINT

US$1.2m

NasdaqCM:NBSE

US$1.4m

OTCPK:CWBR

US$1.5m

NasdaqCM:REVB

US$1.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

New major risk - Shareholder dilution

No longer forecast to breakeven

New major risk - Financial position

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Recent updates

Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

New major risk - Shareholder dilution

No longer forecast to breakeven

New major risk - Financial position

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc Announces Executive Changes

New major risk - Shareholder dilution

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Insufficient new directors

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

New major risk - Market cap size

Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Genprex, Inc. announced delayed 10-Q filing

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate

Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Price target increased to US$6.23

High number of new and inexperienced directors

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

Price target increased to US$6.50

High number of new and inexperienced directors

Genprex, Inc. Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancercer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Genprex, Inc. Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Genprex, Inc. Announces Positive Preclinical Data for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System for Delivery of FAS DNA Plasmid to Treat Metastatic Colorectal Cancer

Genprex, Inc. to Accelerate Opening of Acclaim-1 Clinical Trial Sites

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

Genprex: Limited Clinical Data To Justify Risk

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Genprex, Inc.(NasdaqCM:GNPX) dropped from Russell 3000E Index

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$8.25

Forecast to breakeven in 2024

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer

Genprex receives IRB approval for NSCLC gene therapy trial; shares up 4%

Genprex, Inc. Announces Formation of Clinical Advisory Board